Management of Persistent Flu-Like Symptoms
Diagnostic Considerations
- The American Thoracic Society recommends performing urgent evaluation for pneumonia and bacterial coinfection in patients who fail to improve after 3-5 days of illness or who deteriorate after initial improvement 1
- Respiratory deterioration indicators such as new or worsening dyspnoea, productive cough, chest pain, or oxygen saturation <92% suggest pneumonia development 2, 3
- Persistent fever beyond 5 days warrants reassessment for complications 4
- Signs of severe illness, including confusion, hypotension, respiratory rate ≥30/min, or tachycardia, indicate potential severe pneumonia or sepsis 5, 3
Diagnostic Workup
- A chest radiograph is mandatory for all patients with persistent symptoms to identify pneumonia 5, 3
- Complete blood count and inflammatory markers, such as C-reactive protein, urea, electrolytes, and liver function tests, should be performed to assess severity and guide management 5, 3
- Pulse oximetry and arterial blood gases should be performed if oxygen saturation <92% on room air 5, 3
Severity Assessment
- The CURB-65 score should be calculated to assess the severity of pneumonia, with a score of 0-1 indicating possible home treatment, a score of 2 indicating possible hospital admission or supervised outpatient management, and a score of 3-5 indicating urgent hospital referral 5, 3
- Bilateral chest radiograph changes are an automatic indication for hospital admission regardless of CURB-65 score 5, 3
Treatment
- The British Thoracic Society recommends first-line oral therapy with co-amoxiclav or doxycycline for non-severe pneumonia 2, 7
- For severe pneumonia, immediate hospital admission and intravenous antibiotics within 4 hours are required 5, 3
- Oxygen therapy should be provided to maintain PaO₂ >8 kPa and SaO₂ >92% 5, 3
Antiviral Considerations
- Oseltamivir may still be beneficial in severely ill or immunocompromised patients even beyond 48 hours from symptom onset 2, 1
- Antiviral resistance testing should be considered for immunocompromised patients with persistent influenza viral replication after 7-10 days of illness who remain symptomatic 1